The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia

Boehringer Ingelheim

Status: Completed

Conditions: Heart Failure

Treatments: Drug: Mirapexin® (Sifrol®)

Study type: Observational

Funder types: Industry

Identifiers

NCT02236741

248.672

Details and patient eligibility

About

Study to assess the risk of incident heart failure associated with the use of pramipexole compared with other dopamine agonists and additionally, to assess the risk of incident heart failure associated with the use of dopamine agonists in comparison with no use of dopamine agonist therapy

Enrollment: 26,814 patients

Sex: All

Ages: 40 to 89 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients between 40 and 89 years of age who received at least one prescription for anti-parkinsonian drugs during the period 1997-2009

Exclusion criteria

• Patients with a diagnosis of heart failure or with prescriptions for two or more among the digitalis, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blocker (ARB), and diuretic drug classes prior to cohort entry

Trial design

26,814 participants in 1 patient group

users of anti-parkinsonian drugs

Treatment:

Drug: Mirapexin® (Sifrol®)